BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21913031)

  • 1. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.
    Tachibana T; Kato M; Sugiyama Y
    Pharm Res; 2012 Mar; 29(3):651-68. PubMed ID: 21913031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
    Tachibana T; Kato M; Takano J; Sugiyama Y
    Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
    Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption.
    Yoshitomo A; Asano S; Hozuki S; Tamemoto Y; Shibata Y; Hashimoto N; Takahashi K; Sasaki Y; Ozawa N; Kageyama M; Iijima T; Kazuki Y; Sato H; Hisaka A
    Drug Metab Dispos; 2023 Mar; 51(3):318-328. PubMed ID: 36810197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.
    Takano J; Maeda K; Bolger MB; Sugiyama Y
    Drug Metab Dispos; 2016 Nov; 44(11):1808-1818. PubMed ID: 27538919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Simple Decision Tree Suited for Identification of Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation.
    Tomaru A; Toshimoto K; Lee W; Ishigame K; Sugiyama Y
    J Pharm Sci; 2021 Jan; 110(1):510-516. PubMed ID: 33137373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.
    Kato M; Chiba K; Hisaka A; Ishigami M; Kayama M; Mizuno N; Nagata Y; Takakuwa S; Tsukamoto Y; Ueda K; Kusuhara H; Ito K; Sugiyama Y
    Drug Metab Pharmacokinet; 2003; 18(6):365-72. PubMed ID: 15618757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
    Ito K; Kusuhara H; Sugiyama Y
    Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study.
    Watanabe T; Maeda K; Nakai C; Sugiyama Y
    J Pharm Sci; 2013 Sep; 102(9):3196-204. PubMed ID: 23754337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
    Suzuki K; Taniyama K; Aoyama T; Watanabe Y
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.
    Miyake T; Tsutsui H; Haraya K; Tachibana T; Morimoto K; Takehara S; Ayabe M; Kobayashi K; Kazuki Y
    Br J Pharmacol; 2021 Nov; 178(21):4335-4351. PubMed ID: 34232502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
    Yalkinoglu Ö; Becker A; Krebs-Brown A; Vetter C; Lüpfert C; Perrin D; Heuer J; Biedert H; Hirt S; Bytyqi A; Bachmann A; Strotmann R
    Invest New Drugs; 2023 Aug; 41(4):596-605. PubMed ID: 37415001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein.
    Tachibana T; Kato M; Watanabe T; Mitsui T; Sugiyama Y
    Xenobiotica; 2009 Jun; 39(6):430-43. PubMed ID: 19480549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
    Ohno Y; Hisaka A; Ueno M; Suzuki H
    Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of schisandra lignans on the absorption of protopanaxadiol-type ginsenosides mediated by P-glycoprotein and protopanaxatriol-type ginsenosides mediated by CYP3A4.
    Li Y; Yang K; Zhao L; Xu C; Zhou W; Wang Z; Hu H; You Y
    J Ethnopharmacol; 2024 Jan; 318(Pt B):117057. PubMed ID: 37597677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.